Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL.
Article in Cancer discovery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
26 authors.
Yi-Jiun SuDivision of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, California.ORCID 0000-0002-8372-1166
Anne Marijn KramerDivision of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, California.ORCID 0000-0001-5239-7343
Mark P HamiltonDivision of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, California.ORCID 0000-0002-3732-8910
Neha AgarwalDivision of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, California.ORCID 0000-0002-3792-6750
Hrishikesh K SrinageshDivision of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, California.ORCID 0000-0001-9786-3010
John H BairdDivision of Lymphoma, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California.ORCID 0000-0001-8291-6546
Bita SahafCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California.ORCID 0000-0002-4157-3863
Adam KuoCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California.ORCID 0000-0001-9797-0043
Zachary J EhlingerCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California.ORCID 0000-0003-0849-1089
Moksha H DesaiCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California.ORCID 0009-0009-8060-8131
Skyler P RietbergCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California.ORCID 0009-0001-3403-8969
Ramya TunuguntlaCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California.ORCID 0009-0000-8313-6197
Shabnum PatelCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California.ORCID 0000-0002-4782-9540
Harshini ChinnasamyCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California.ORCID 0009-0003-2351-1890
Nikolaos Gkitsas-LongCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California.ORCID 0000-0002-9972-0926
Dorota D KlyszCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California.ORCID 0000-0002-6733-6110
Annie Kathleen BrownCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California.ORCID 0000-0002-3890-5193
Sushma BharadwajDivision of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, California.ORCID 0009-0002-9079-9591
Saurabh DahiyaDivision of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, California.ORCID 0000-0001-8291-1796
Melody SmithDivision of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, California.ORCID 0000-0002-2702-0381
Lori MufflyDivision of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, California.ORCID 0000-0002-9887-6136
Crystal L MackallDivision of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, California.ORCID 0000-0003-0359-9023
Zinaida GoodCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California.ORCID 0000-0003-2343-5771
Steven A FeldmanCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California.ORCID 0000-0003-2098-3860
David B MiklosDivision of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, California.ORCID 0000-0003-0717-4305
Matthew J FrankDivision of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, California.ORCID 0000-0002-2356-3354
Funding
Lymphoma Antigen Density and Circulating Tumor DNA Profiling As Determinants of Novel CAR TherapiesK08CA248968 · NCI · STANFORD UNIVERSITY · PI FRANK, MATTHEW J. · 2020 to 2024
$845k
National Cancer Institute (NCI) K08CA248968NCI NIH HHS K08 CA248968
6 · The paper itself
Abstract
significanceLate leukapheresis (>6 months after CAR19) resulted in less residual CAR19, higher CAR22 CD4+ naïve T and TCM cells, less TEM cells, and higher CD8+ TCM cells, but similar clinical outcomes to those with early leukapheresis. CAR22 responses were associated with higher transduction efficiency and CD8+ TCM and less CD8+ TEM cells.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL. · full record | Socratic